FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2071051025> ?p ?o ?g. }

• W2071051025 endingPage "P04.134" @default.
• W2071051025 startingPage "P04.134" @default.
• W2071051025 abstract "Objective: Evaluate long-term safety, efficacy, and associations between baseline treatment history and postbaseline annualized relapse rate (ARR) in multiple sclerosis (MS) patients treated with natalizumab. Background The ongoing natalizumab (TYSABRI®) Observational Program (TOP) study is an open-label, multinational, observational study assessing long-term outcomes in relapsing-remitting MS patients in the postmarketing setting in Europe, Australia, and Canada. Design/Methods: As of June 2011, 3484 patients from 15 countries were enrolled. Incidence of serious adverse events (SAEs) was analyzed. ARR and Expanded Disability Status Scale (EDSS) scores were assessed. Associations between baseline therapy and postbaseline ARR were analyzed using negative binomial regression for 5 baseline groups: therapy naive (n=337), interferon (IFN) only (n=1626), glatiramer acetate (GA) only (n=288), switched between GA and IFN in either order (n=595), or immunosuppressant (IS) use (n=487). Results: - 53]) natalizumab infusions. Overall, 5.1% of patients experienced ≥1 SAE; infections (1.1%) and hypersensitivity reactions (0.7%) were most frequent. Seven cases of progressive multifocal leukoencephalopathy (PML) occurred after 35, 29, 28, 26, 24, 24, and 12 natalizumab infusions. Three of them were previously exposed to mitoxantrone. Overall, the mean EDSS score was 3.5 at baseline and 3.4 after 3 years. ARR was significantly decreased regardless of baseline treatment history; mean ARR decreased (n=3458) from baseline (1.98) to postbaseline (0.28; P Conclusions: The overall incidence and type of SAEs reported in TOP are consistent with natalizumab9s known safety profile. EDSS scores were stable and ARR was significantly reduced after 3 years of natalizumab therapy. ARRs were lowest in therapy-naive patients and highest in patients with prior IS. Supported by: Biogen Idec Inc. and Elan Pharmaceuticals, Inc. Disclosure: Dr. Kappos has received research support from Acorda Therapeutics, Actelion, Allozyne, BaroFold, Inc., Bayer Pharmaceuticals Corporation, Bayhill Therapeutics, Biogen Idec, Boehringer Ingelheim Pharmaceuticals, Inc, Elan Corporation, Genmab, GlaxoSmithKline, Inc., Glenmark Pharma, Merck Serono, MediciNova, Novartis, Sanofi-Aventis Pharmaceuticals, Santhera Pharmaceuticals, Shire, Roche Diagnostics, Teva Neuroscience, UCB Pharma, Pfizer Inc, Swiss MS Society, Swiss National Research Foundation, European Union, Gianni Rubatto Foundation, Novartis and Roche Research Foundations. Dr. Belachew has received personal compensation for activities with Bayer Pharmaceuticals Corporation, Biogen Idec and Merck Serono as a consultant. Dr. Belachew has received research support from Biogen Idec, Merck Serono, Novartis, Sanofi-Aventis Pharmaceuticals, and Teva Neuroscience. Dr. Butzkueven has received personal compensation for activities with Biogen Idec, Merck Serono, Novartis, Sanofi-Aventis Pharmaceuticals, Inc., National Health and Medical Research Council, and National MS Society. Dr. Butzkueven has received personal compensation in an editorial capacity for Multiple Sclerosis International Federation and Multiple Sclerosis. Dr Butzkueven has received research support from Biogen Idec, Merck Serono, and Novartis. Dr. Pellegrini has received personal compensation for activities with Biogen Idec as a consultant. Dr. Trojano has received personal compensation for activities with Bayer Pharmaceuticals Corporation, Biogen Idec and Sanofi-Aventis Pharmaceuticals, Inc. as a consultant and/or speaker. Dr. Trojano has received research support from Merck & Co., Inc. Dr. Wiendl has received personal compensation for activities with Bayer Pharmaceuticals Corporation, Biogen Idec, Merck Serono, Novo Nordisk, Sanofi-Aventis Pharmaceuticals, Inc., Schering AG and Teva Neuroscience. Dr. Wiendl has received research support from Bayer Pharmaceuticals Corporation, Biogen Idec, Medac, Merck-Serono, Novo Nordisk, Sanofi-Aventis Pharmaceuticals, Inc., Schering AG and Teva Neuroscience. Dr. Zhang has received personal compensation for activities with Biogen Idec as an employee. Dr. Hotermans has received personal compensation for activities with Biogen Idec as an employee.Dr. Hotermans holds stock and/or stock options in Biogen Idec which sponsored research in which Dr. Hotermans was involved as an investigator." @default.
• W2071051025 created "2016-06-24" @default.
• W2071051025 creator A5021855649 @default.
• W2071051025 creator A5023725739 @default.
• W2071051025 creator A5028230236 @default.
• W2071051025 creator A5038373894 @default.
• W2071051025 creator A5050442625 @default.
• W2071051025 creator A5054874316 @default.
• W2071051025 creator A5065247578 @default.
• W2071051025 creator A5077574989 @default.
• W2071051025 date "2012-04-22" @default.
• W2071051025 modified "2023-09-22" @default.
• W2071051025 title "Long-Term Safety and Efficacy and Association between Baseline Treatment History and Postbaseline Relapses in Multiple Sclerosis Patients Treated with Natalizumab in the TYSABRI(R) Observational Program (TOP) (P04.134)" @default.
• W2071051025 doi "https://doi.org/10.1212/wnl.78.1_meetingabstracts.p04.134" @default.
• W2071051025 hasPublicationYear "2012" @default.
• W2071051025 type Work @default.
• W2071051025 sameAs 2071051025 @default.
• W2071051025 citedByCount "5" @default.
• W2071051025 countsByYear W20710510252012 @default.
• W2071051025 countsByYear W20710510252013 @default.
• W2071051025 countsByYear W20710510252014 @default.
• W2071051025 crossrefType "journal-article" @default.
• W2071051025 hasAuthorship W2071051025A5021855649 @default.
• W2071051025 hasAuthorship W2071051025A5023725739 @default.
• W2071051025 hasAuthorship W2071051025A5028230236 @default.
• W2071051025 hasAuthorship W2071051025A5038373894 @default.
• W2071051025 hasAuthorship W2071051025A5050442625 @default.
• W2071051025 hasAuthorship W2071051025A5054874316 @default.
• W2071051025 hasAuthorship W2071051025A5065247578 @default.
• W2071051025 hasAuthorship W2071051025A5077574989 @default.
• W2071051025 hasConcept C118552586 @default.
• W2071051025 hasConcept C121332964 @default.
• W2071051025 hasConcept C126322002 @default.
• W2071051025 hasConcept C12725497 @default.
• W2071051025 hasConcept C142853389 @default.
• W2071051025 hasConcept C15744967 @default.
• W2071051025 hasConcept C17744445 @default.
• W2071051025 hasConcept C1862650 @default.
• W2071051025 hasConcept C199539241 @default.
• W2071051025 hasConcept C23131810 @default.
• W2071051025 hasConcept C2780640218 @default.
• W2071051025 hasConcept C2781004633 @default.
• W2071051025 hasConcept C542102704 @default.
• W2071051025 hasConcept C61797465 @default.
• W2071051025 hasConcept C62520636 @default.
• W2071051025 hasConcept C71924100 @default.
• W2071051025 hasConceptScore W2071051025C118552586 @default.
• W2071051025 hasConceptScore W2071051025C121332964 @default.
• W2071051025 hasConceptScore W2071051025C126322002 @default.
• W2071051025 hasConceptScore W2071051025C12725497 @default.
• W2071051025 hasConceptScore W2071051025C142853389 @default.
• W2071051025 hasConceptScore W2071051025C15744967 @default.
• W2071051025 hasConceptScore W2071051025C17744445 @default.
• W2071051025 hasConceptScore W2071051025C1862650 @default.
• W2071051025 hasConceptScore W2071051025C199539241 @default.
• W2071051025 hasConceptScore W2071051025C23131810 @default.
• W2071051025 hasConceptScore W2071051025C2780640218 @default.
• W2071051025 hasConceptScore W2071051025C2781004633 @default.
• W2071051025 hasConceptScore W2071051025C542102704 @default.
• W2071051025 hasConceptScore W2071051025C61797465 @default.
• W2071051025 hasConceptScore W2071051025C62520636 @default.
• W2071051025 hasConceptScore W2071051025C71924100 @default.
• W2071051025 hasIssue "Meeting Abstracts 1" @default.
• W2071051025 hasLocation W20710510251 @default.
• W2071051025 hasOpenAccess W2071051025 @default.
• W2071051025 hasPrimaryLocation W20710510251 @default.
• W2071051025 hasRelatedWork W129524245 @default.
• W2071051025 hasRelatedWork W2056978592 @default.
• W2071051025 hasRelatedWork W2151867003 @default.
• W2071051025 hasRelatedWork W2731280721 @default.
• W2071051025 hasRelatedWork W2924049204 @default.
• W2071051025 hasRelatedWork W3011591829 @default.
• W2071051025 hasRelatedWork W3037954235 @default.
• W2071051025 hasRelatedWork W3104226692 @default.
• W2071051025 hasRelatedWork W4238977932 @default.
• W2071051025 hasRelatedWork W2737631285 @default.
• W2071051025 hasVolume "78" @default.
• W2071051025 isParatext "false" @default.
• W2071051025 isRetracted "false" @default.
• W2071051025 magId "2071051025" @default.
• W2071051025 workType "article" @default.